0000950170-24-082416.txt : 20240709
0000950170-24-082416.hdr.sgml : 20240709
20240709161503
ACCESSION NUMBER: 0000950170-24-082416
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240705
FILED AS OF DATE: 20240709
DATE AS OF CHANGE: 20240709
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dunn Edmund
CENTRAL INDEX KEY: 0001989401
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40522
FILM NUMBER: 241107618
MAIL ADDRESS:
STREET 1: MONTE ROSA THERAPEUTICS, INC.
STREET 2: 321 HARRISON AVENUE, SUITE 900
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Monte Rosa Therapeutics, Inc.
CENTRAL INDEX KEY: 0001826457
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 HARRISON AVENUE
STREET 2: SUITE 900
CITY: BOSTON
STATE: MA
ZIP: 02118
BUSINESS PHONE: 617-949-2643
MAIL ADDRESS:
STREET 1: 321 HARRISON AVENUE
STREET 2: SUITE 900
CITY: BOSTON
STATE: MA
ZIP: 02118
4
1
ownership.xml
4
X0508
4
2024-07-05
0001826457
Monte Rosa Therapeutics, Inc.
GLUE
0001989401
Dunn Edmund
MONTE ROSA THERAPEUTICS, INC.
321 HARRISON AVENUE, SUITE 900
BOSTON
MA
02118
false
true
false
false
Principal Accounting Officer
false
Common Stock
2024-07-05
4
S
false
1610
3.8301
D
13944
D
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.83 to $3.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
/s/ Phil Nickson, Attorney-in-Fact
2024-07-09